// App-Quantinova.ai

1432 : Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (?60 years) With Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Nitin Jain

Principal Investigators

  • Susan -Brien

  • Deborah A. Thomas

  • Elias Jabbour

  • Stefan Faderl

  • Farhad Ravandi

  • Gautam Borthakur

  • Sergernne York

  • Rebecca Garris

  • Jorge Cortes

  • Hagop M. Kantarjian

Medical Centers

  • Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Thrombocytopenia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Cytarabine liposomal

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved